Sculptra: Cost, Results Timeline and How Many Vials You Need

Sculptra is the brand name for an injectable made of poly-L-lactic acid (PLLA) — a material that reaches the clinic as a freeze-dried powder and has to be mixed with sterile water before any injection.

FDA records list the maker as Galderma/Q-Med, and the product's approval is PMA P030050, the premarket-approval route FDA uses for dermal fillers, which it regulates as medical device implants.

So yes, Sculptra is in the filler family: FDA groups poly-L-lactic acid with hyaluronic acid and calcium hydroxylapatite as the absorbable (temporary) filler materials, in contrast to the one permanent filler material it has approved. What makes it behave differently is what the maker emphasizes: Galderma calls Sculptra a "biostimulatory aesthetic injectable" and says it works by stimulating the body's own natural collagen production.

Practically, that shows up as timing — Sculptra's correction builds gradually over a series of sessions, rather than appearing on the day of treatment.

The approvals are narrow.

FDA approved Sculptra on 2004-08-03 for HIV-associated facial fat loss (lipoatrophy); on 2009-07-28, under the name Sculptra Aesthetic, for shallow to deep nasolabial fold contour deficiencies and other facial wrinkles in immune-competent people; and on 2023-04-25 for fine lines and wrinkles in the cheek region.

The Sculptra and Sculptra Aesthetic names were merged under the single trade name Sculptra in 2021.

Those three uses are the entire label — every other area or purpose is off-label.

Age is part of the approval picture too: FDA states dermal fillers are approved for adults aged 22 or older (over 21), with each product's label setting the exact age.

For how Sculptra compares with the other materials and brands, see dermal fillers, the category overview.

Sculptra is supplied as a lyophilized (freeze-dried) powder of poly-L-lactic acid microparticles, with sodium carboxymethylcellulose and mannitol, in 367.5 mg vials meant for one patient and one session.

Before injection it must be reconstituted with sterile water — either 5 mL, left to stand for at least 2 hours and usable for up to 72 hours, or 8 mL with an optional 1 mL of 2% lidocaine for immediate use.

The first day can mislead you.

The label says the fullness right after a session is mostly water swelling: it resolves within hours to a few days, and the original contour deficiency reappears.

The correction that lasts develops gradually after that, as the treatment effect builds.

That pattern is why the label's instructions run against filler instincts.

The contour deficiency should be under-corrected at every session — never fully corrected or overfilled — and at least 3 to 4 weeks should pass before the provider reassesses; patients are told up to four injection sessions may be needed.

In the cheek-wrinkle trial, sessions were spaced four weeks apart, for a maximum of four.

Galderma says the mechanism is collagen — that Sculptra works by stimulating the body's own natural collagen production.

The label itself frames the effect conservatively: correction develops gradually, session by session, and its safety-and-effectiveness findings cover only the approved uses.

All three approvals are facial.

On-label Sculptra means: HIV-associated facial fat loss; shallow to deep nasolabial fold contour deficiencies and other facial wrinkles; and fine lines and wrinkles in the cheek region.

The cheek indication is worded narrowly — fine lines and wrinkles in the cheek region, not "cheek volume" — and no other use is on the product's US label.

The label also draws lines inside the face.

Sculptra must not be injected into the red part (vermilion) of the lips, and its use in the lips and the periorbital area — around the eyes — has not been studied; the label notes literature reporting more nodules around the eyes.

Lip augmentation has its own approved products — a separate list — covered in lip filler.

Use outside those three approvals is off-label.

The label states that safety and effectiveness have not been evaluated when Sculptra is injected in larger amounts, at different frequencies, or at sites other than its approved uses — which puts temples, jawline, buttocks, hips and thighs outside the label.

For the body, FDA's position is stronger still: it recommends against using any dermal filler for body contouring, including increasing breast or buttock size, and says those uses are not FDA-approved.

For the buttock use specifically, see does a Sculptra butt lift work.

Two heavily marketed uses deserve plain wording. "Ozempic face" treatment: no dermal filler, Sculptra included, has an FDA indication for weight-loss or GLP-1-related facial volume loss.

Galderma markets a "SCULPT & LIFT" regimen for the post-weight-loss face and calls it "the first clinically proven facial aesthetic injectable treatment" for this — a manufacturer's marketing claim, not an approval.

The "Sculptra BBL": buttock and hip augmentation is off-label, and the published evidence is thin.

A 2020 review called the literature sparse; a 2023 systematic review found only 12 mostly strongly biased reports on filler buttock augmentation and warned that serious complications occur; and one retrospective series of 60 women concluded visible results took at least 20 vials in total, with vial counts "based on the patient budget."

Sculptra is measured in vials, and the label's numbers are maximums for the studied areas, not a standard prescription.

Per session, the label allows up to 4.5 mL per nasolabial fold (with the 8 mL reconstitution) and up to 9 mL per cheek for cheek wrinkles — one full reconstituted vial per side.

In the cheek trial, subjects received at most two vials per session, one per side.

Beyond those maximums, the label gives no vial counts for full-face, temple, jawline or body treatment — those areas are outside the approvals.

What exists is the trial record: in the cheek-wrinkle study of 97 treated subjects, up to four sessions were spaced four weeks apart, and 95, 86 and 67 subjects returned for a second, third and fourth session.

The median injected volume was 16.0 mL per session across both sides, and the mean total was 54.11 mL per subject — about six 9 mL vials, an estimate calculated from the trial mean, not a dose to expect.

Cost follows the vial: Sculptra is priced per vial, so a quote is built from the number of vials a provider proposes and how many sessions the plan takes.

ASPS lists an average cost of $901 for non-hyaluronic acid fillers — the category that holds Sculptra, Radiesse and Bellafill.

Read that figure for what it is: an average fee reported by ASPS member plastic surgeons, not a med spa price, with no data year stated and no clarity on whether it covers one syringe or a whole treatment.

ASPS says filler cost varies with the injector's expertise and qualifications, the type of procedure, the time and effort required and the office's location — and that health insurance does not cover dermal fillers.

Galderma runs a rewards program for its injectables.

Per Galderma's published program pages, ASPIRE Rewards gives a $20-off welcome reward, 100 points equal a $10 reward, and Sculptra earns 200 points per vial up to 600 points per visit, with program maximums per visit and per year.

Terms change, so check them before booking.

We have not confirmed a national med spa price for Sculptra on this page — the numbers that matter are the per-vial price at the clinics you contact and how many vials they propose.

For whether patients feel it was worth it, see Sculptra reviews.

The honest sequence, from the label: right after a session, the area looks corrected — but that fullness is mostly injected water, and it resolves within hours to a few days, at which point the original deficiency reappears.

After that, the treatment effect builds and the depression gradually improves.

The label tells the provider to wait at least 3 to 4 weeks before reassessing, and patients are told up to four sessions may be needed.

For photos of outcomes, see what Sculptra results look like.

Independent and manufacturer timelines line up with that.

The American Academy of Dermatology says most fillers show results immediately, but poly-L-lactic acid (Sculptra) shows results in 2 to 3 weeks and builds over time.

Galderma says results can be seen as early as 1 month after treatment.

A full course is a series: in the cheek trial, up to four sessions ran four weeks apart, and 95 of the 97 treated subjects came back for at least a second session.

Aftercare is part of the labeled protocol.

The label recommends massaging the treated areas for five minutes, five times a day, for five days after each session — the "5-5-5" rule — to promote a natural-looking correction, and applying a cloth-wrapped ice pack in the first 24 hours.

The duration numbers in the label come from the cheek-wrinkle study, and they measured responders, not permanence.

At month 12, 70.7% of treated subjects were still responders — at least a one-grade improvement on both cheeks, rated by a blinded evaluator — versus 25.9% of untreated controls.

In the extension study, 76.9% (50 of 65 treated subjects) were still responders at month 24.

Those are trial figures for one product, one area and one protocol — they are not what any individual will get.

Galderma says Sculptra results can last up to 2 years, and FDA's material-level estimate for poly-L-lactic acid is also up to 2 years, with results appearing gradually over several weeks.

FDA counts PLLA among the absorbable — temporary — filler materials, not permanent ones.

The label adds a candid unknown: the kinetics of PLLA resorption in humans have not been determined.

In a rabbit study, relatively large PLLA remnants were still visible 64 weeks after implantation — a reminder that how long a result lasts and how long material remains in tissue are different questions.

The everyday effects are the ones the label describes for injection generally: redness, swelling or bruising that typically resolves within hours to one week, and hematoma — a collection of blood at the site — within about two weeks.

Makeup may be applied a few hours after treatment if there are no complications.

For the full picture, see Sculptra side effects.

A different effect runs on a longer clock: delayed papules and nodules — small lumps under the skin that appear days to months after injection and follow a prolonged course.

The label describes them as usually palpable rather than visible, and painless.

In the US 5-year post-approval study — 867 subjects treated with the 5 mL reconstitution, with investigators confirming reported lumps — nodules or papules occurred in 28.5% of subjects overall: 27.2% with marionette-line treatment and 19.0% with nasolabial folds.

Timing comes from the original nasolabial trial: nodules appeared a median 160 days after the first session, papules a median 55 days, and nodules lasted a median 100 days.

The label says delayed nodules usually appear 3 to 4 months after treatment and may require corticosteroid injections, subcision or excision.

It also ties risk to technique and volume: superficial injection raises nodule risk, and higher volumes — especially more than 2 mL per marionette line — were associated with more nodules in the post-approval study.

And the property that reframes all of it: Sculptra cannot be dissolved with hyaluronidase the way hyaluronic acid fillers can — the enzyme breaks down hyaluronic acid only, and it does not dissolve poly-L-lactic acid.

The label's treatment list — massage, corticosteroids, saline injections, subcision and surgery among the options it names — manages specific problems rather than undoing the product.

That is the backdrop to the label's insistence on under-correction and patience between sessions.

FDA's advice for fillers applies word for word here: choose a licensed health care provider with dermatology or plastic-surgery experience who is trained in filler injection, and treat the appointment as what FDA says it is — a medical procedure, not a cosmetic treatment.

Cost varies with the injector's expertise and qualifications, the type of procedure, the time and effort required and the office's location — the factors ASPS names — so the useful comparison work is local.

The last question is not hypothetical caution.

FDA tells injectors to know the signs of intravascular injection, to keep an updated plan for treating it — on-site treatment and/or immediate referral — and to stop injecting at signs such as skin blanching, vision change, stroke signs or unusual pain.

A clinic that answers it easily is showing you the preparation FDA describes.